Relay Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RLAY research report →
Range $26 – $31
Price Chart
About the company
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions.
- CEO
- Sanjiv K. Patel
- IPO
- 2020
- Employees
- 202
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on RLAY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $3.52B
- P/E
- -10.54
- PEG
- -0.70
- P/S
- 339.66
- P/B
- 4.26
- EV/EBITDA
- -11.71
- Div Yield
- 0.00%
- Gross Margin
- 89.34%
- Op Margin
- -3094.59%
- Net Margin
- -2837.03%
- ROE
- -40.25%
- ROIC
- -37.86%
Latest fiscal year · YoY change
- Revenue
- $15.36M+53.4%
- Gross Profit
- $11.80M+103.9%
- Op Income
- $-302,738,000
- Net Income
- $-276,479,000+18.1%
- EPS
- $-1.61+31.8%
- OCF Growth
- +5.5%
- FCF Growth
- +6.1%
- Beta
- 1.74
- RSI (14)
- 38
No earnings-call transcripts are available for RLAY yet.
- Free Float
- 78.3%
- Shares Outstanding
- 220.96M
- Float Shares
- 173.08M
of shares held by institutions
270 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for RLAY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Jul 12, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Sb Investment Advisers (Uk) Ltd | 27.90M | 0 |
| Fmr LLC | 24.24M | ▲ 4.13M |
| Casdin Capital, LLC | 16.04M | ▲ 1.62M |
| Blackrock, Inc. | 15.29M | ▲ 2.31M |
| Perceptive Advisors LLC | 14.11M | ▲ 4.36M |
| Commodore Capital LP | 12.00M | ▼ 5.00M |
| Vanguard Group Inc | 9.69M | ▲ 295.70K |
| State Street Corp | 9.15M | ▼ 974.24K |
| Vanguard Capital Management LLC | 8.96M | ▲ 1.58M |
| Price T Rowe Associates Inc | 7.71M | ▲ 5.78M |
| Nextech Invest Ltd. | 6.78M | ▲ 1.25M |
| Bellevue Group AG | 6.19M | ▼ 1.61M |
Held by 366 ETFs
Biggest fund positions in RLAY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 28, 26 | Rahmer Peter | sell | 753 |
| Oct 28, 26 | Bergstrom Donald A | sell | 2,252 |
| Oct 28, 26 | Catinazzo Thomas | sell | 1,469 |
| Oct 7, 26 | Patel Sanjiv | sell | 48,199 |
| Oct 6, 26 | Catinazzo Thomas | sell | 17,511 |
| Oct 6, 26 | Catinazzo Thomas | sell | 206 |
| Sep 8, 26 | Bergstrom Donald A | sell | 8,530 |
| Sep 8, 26 | Catinazzo Thomas | sell | 17,717 |
| Sep 8, 26 | Patel Sanjiv | sell | 48,199 |
| Aug 26, 26 | Rahmer Peter | sell | 4,508 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RLAY coverage
Recent articles, reports, and earnings notes.
Want a deeper read on RLAY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
